Category: Sanofi-AventisSyndicate content

BAX drops FloSeal case against J&J | Medtech legal news for the week of April 13, 2015

April 13, 2015 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Baxter drops FloSeal case against J&J; Feds: We got $119m in fraud penalties from medtech companies last year; Insurer, DJO Global settle pain pump suit

Baxter drops FloSeal case against J&J

April 6, 2015 by Brad Perriello

YYmeta

Feds: We got $119m in fraud penalties from medtech companies last year

April 8, 2015 by Brad Perriello

The U.S. Health & Human Services Dept. and the Justice Dept. say they collected some $119 million in healthcare fraud penalties from medical device companies during fiscal 2014.

Feds: We got $119m in fraud penalties from medtech companies last year

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Report: Smith & Nephew CEO Bohoun to stay put

December 1, 2014 by Brad Perriello

Smith & Nephew CEO Olivier Bohuon reportedly tells employees that he's not in the running for the top job at French drug maker Sanofi.

Report: Smith & Nephew CEO Bohoun to stay put

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Smith & Nephew's Bohuon seen as strong candidate for top Sanofi job

November 4, 2014 by MassDevice

Smith & Nephew CEO Olivier Bohuon is said to be a leading candidate for the top job at French drugmaker Sanofi, which axed its CEO last week without a replacement.

YYmeta

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Diabetes: Medtronic and Sanofi ally on new drug-device combinations

June 16, 2014 by Arezu Sarvestani

Medtronic and Sanofi embark on a global alliance to combine human and financial resources in the interest of new products and services for patients with diabetes.

Diabetes: Medtronic and Sanofi ally for drug-device combinations

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Whistleblower lawsuit costs Genzyme $22M

January 3, 2014 by Arezu Sarvestani

Sanofi subsidiary Genzyme agrees to pay $22.3 million to settle accusations that its sales rep encouraged off-label use of the Seprafilm surgical product.

Whistleblower lawsuit costs Genzyme $22M

Massachusetts-based Genzyme Corp., a subsidiary of Sanofi (NYSE:SNY), agreed to pay $22.3 million to settle a whistleblower lawsuit accusing the company of off-label marketing of its Seprafilm surgical product.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Brokers plead guilty to insider trading of Stryker stock

November 14, 2013 by Brad Perriello

A pair of brokers plead guilty to charges of insider trading in Stryker Corp. stock ahead of its 2011 acquisition of Orthovita.

Brokers plead guilty to insider trading of Stryker stock

A pair of brokers pleaded guilty to federal insider trading charges yesterday, admitting that they used tips from a former Stryker (NYSE:SYK) marketing executive to make illicit trades ahead of the medical device company's 2011 acquisition of Orthovita.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.